Javascript must be enabled to continue!
The pacemaker ventricular lead position and outcomes in patients upgrading to crt
View through CrossRef
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
Adverse hemodynamic effects of right ventricular pacing are known, and the optimal right ventricular lead position is still being a matter of debate. According to the guidelines, upgrade to cardiac resynchronization therapy (CRT) is recommended in patients with indication for pacemaker and left ventricular ejection fraction less than 50% or who need more than 40% of ventricular pacing.
Purpose
To compare clinical outcomes and ejection fraction in patients with previous pacemaker (apical versus septal right ventricular pacing) who are upgrated to CRT.
Methods
Single-center retrospective study of 94 consecutive patients who had previous pacemaker and upgraded to CRT over a 4-year period. Of these patients, 64 had previous apical lead pacemaker and 30 had previous septal lead pacemaker. Data on comorbidities, New York Heart Association (NYHA), left ventricular ejection fraction and hospitalizations due to heart failure were collected.
The results were obtained using Chi-square, Mann-Whitney and t-test.
Results
Patients with septal pacemaker had significantly more diabetes (p = 0.04) and chronic obstructive pulmonary disease (p = 0.01), tended to be more symptomatic (p = 0.198) and had more days of hospitalization before and after pacemaker implantation (12 ± 3 versus 7 ± 2 days and 8 ± 4 versus 3 ± 1 days, respectively), mostly due heart failure decompensation.
Although there were no significant differences in the initial ejection fraction in patients with apical or septal pacemaker implantation (31.2 ± 1.2% and 29.1 ± 1.5%, respectively, p = 0.323), the time to upgrade to CRT was significantly shorter in patients with septal pacemaker implantation (1999 ± 227 days versus 3005 ± 279 days, p = 0.005).
After upgrading to CRT, patients with apical lead had a significant increase in ejection fraction (8.2%, p = 0.011), while patients with septal lead had a non-significant improvement of ejection fraction (4.5%, p = 0.448). In both, apical and septal lead patients, there was a significant improvement in NYHA class after upgrade to CRT (p = 0.03 and p = 0.02, respectively).
Conclusion
Although patients with septal lead had more comorbidities and hospitalizations due to heart failure, they do not benefit from the upgrade to CRT, unlike what happens in patients with apical lead. These findings can be explained by the fact that the septal lead minimizes ventricular desynchrony induced by right ventricular pacing.
Oxford University Press (OUP)
Title: The pacemaker ventricular lead position and outcomes in patients upgrading to crt
Description:
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
Adverse hemodynamic effects of right ventricular pacing are known, and the optimal right ventricular lead position is still being a matter of debate.
According to the guidelines, upgrade to cardiac resynchronization therapy (CRT) is recommended in patients with indication for pacemaker and left ventricular ejection fraction less than 50% or who need more than 40% of ventricular pacing.
Purpose
To compare clinical outcomes and ejection fraction in patients with previous pacemaker (apical versus septal right ventricular pacing) who are upgrated to CRT.
Methods
Single-center retrospective study of 94 consecutive patients who had previous pacemaker and upgraded to CRT over a 4-year period.
Of these patients, 64 had previous apical lead pacemaker and 30 had previous septal lead pacemaker.
Data on comorbidities, New York Heart Association (NYHA), left ventricular ejection fraction and hospitalizations due to heart failure were collected.
The results were obtained using Chi-square, Mann-Whitney and t-test.
Results
Patients with septal pacemaker had significantly more diabetes (p = 0.
04) and chronic obstructive pulmonary disease (p = 0.
01), tended to be more symptomatic (p = 0.
198) and had more days of hospitalization before and after pacemaker implantation (12 ± 3 versus 7 ± 2 days and 8 ± 4 versus 3 ± 1 days, respectively), mostly due heart failure decompensation.
Although there were no significant differences in the initial ejection fraction in patients with apical or septal pacemaker implantation (31.
2 ± 1.
2% and 29.
1 ± 1.
5%, respectively, p = 0.
323), the time to upgrade to CRT was significantly shorter in patients with septal pacemaker implantation (1999 ± 227 days versus 3005 ± 279 days, p = 0.
005).
After upgrading to CRT, patients with apical lead had a significant increase in ejection fraction (8.
2%, p = 0.
011), while patients with septal lead had a non-significant improvement of ejection fraction (4.
5%, p = 0.
448).
In both, apical and septal lead patients, there was a significant improvement in NYHA class after upgrade to CRT (p = 0.
03 and p = 0.
02, respectively).
Conclusion
Although patients with septal lead had more comorbidities and hospitalizations due to heart failure, they do not benefit from the upgrade to CRT, unlike what happens in patients with apical lead.
These findings can be explained by the fact that the septal lead minimizes ventricular desynchrony induced by right ventricular pacing.
Related Results
Upgrade pacemaker to CRT: predictors and the importance of LVEF
Upgrade pacemaker to CRT: predictors and the importance of LVEF
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
...
Calreticulin Promotes Immunity Against Acute Myeloid Leukemia Cells in Vivo
Calreticulin Promotes Immunity Against Acute Myeloid Leukemia Cells in Vivo
Abstract
Pre-apoptotic cancer cells release internalized calreticulin (CRT) to their surface prior to death, which acts as an ‘eat-me’ signal to local phagocytes. Ch...
Impact of deactivated CRT on ventricular arrhythmia occurrence and survival in LVAD patients
Impact of deactivated CRT on ventricular arrhythmia occurrence and survival in LVAD patients
Abstract
Background
The majority of LVAD patients with an active CRT device are CRT non-responders. Currently, there is n...
Molecular and Functional Analysis of Calcium Binding by a Cancer-linked Calreticulin Mutant
Molecular and Functional Analysis of Calcium Binding by a Cancer-linked Calreticulin Mutant
Abstract
Calreticulin (CRT) is an endoplasmic reticulum (ER) chaperone with low affinity calcium binding sites in its C-terminal domain. This reg...
Clinical Characteristics and Outcomes of Older Cardiac Resynchronization Therapy Recipients Using a Pacemaker versus a Defibrillator
Clinical Characteristics and Outcomes of Older Cardiac Resynchronization Therapy Recipients Using a Pacemaker versus a Defibrillator
CRT‐P versus CRT‐D OutcomesBackgroundCardiac resynchronization therapy (CRT) is commonly used to manage heart failure, yet published guidelines do not distinguish between recommend...
Outcomes of cardiac resynchronisation therapy in patients with heart failure with atrial fibrillation: a systematic review and meta-analysis of observational studies
Outcomes of cardiac resynchronisation therapy in patients with heart failure with atrial fibrillation: a systematic review and meta-analysis of observational studies
Background
Cardiac resynchronisation therapy (CRT) is beneficial in selected patients with heart failure (HF) in normal sinus rhythm (NSR). We sought to evaluate ...
81 Suitability of cardiac resynchronisation therapy in patients with univentricular and systemic right ventricular hearts
81 Suitability of cardiac resynchronisation therapy in patients with univentricular and systemic right ventricular hearts
Introduction
Cardiac resynchronisation therapy (CRT) is a well-recognised treatment in patients with systolic heart failure complicated by ventricular dyssychrony...
Regional myocardial wall asymmetry as a novel echocardiographic predictor of response to resynchronization, preliminary single-centre data
Regional myocardial wall asymmetry as a novel echocardiographic predictor of response to resynchronization, preliminary single-centre data
Abstract
Background
According to current guidelines, the indications for cardiac resynchronization therapy (CRT) are dete...

